RxDoctor Payments Data

Micah Fisher, MD

Pulmonary Disease · Atlanta, GANPI 1477545499

Payments from drug & device makers

What this record shows

This record is dominated by education: $58 of the $88 with a category attached, or 65.3%. Merck accounts for 65.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $58 and has fallen 68.8% since, to $18 in 2024. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.

$88in general payments, 2019–2025

Across 5 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$58
  • Edwards Lifesciences$18
  • Genentech USA, Inc.$12
$1,241,360in research payments, 2019–2025

Across 155 payments — averaging $8008.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$821K
  • United Therapeutics Corporation$356K
  • Janssen Research & Development, LLC$46K
  • Novartis$11K
  • Pfizer$3K
  • Actelion Pharmaceuticals, Ltd$2K
  • plus $2K from 1 others

What the payments were for

  • Food & beverage$3135%
  • Education$5865%

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck3$58
Edwards Lifesciences1$18
Genentech USA, Inc.1$12

How this compares

$88 in reported general payments places this provider in the 10th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$87,368
Medicare patients
562
Services billed
1,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat84$1,122,287
OpsumitMacitentan81$1,024,239
Ambrisentan362$953,615
Tyvaso DpiTreprostinil35$897,753
UptraviSelexipag38$880,131
WinrevairSotatercept-Csrk59$830,464
LetairisAmbrisentan40$482,983
Bosentan88$252,948
Tadalafil245$198,853
EliquisApixaban147$119,721
Orenitram ErTreprostinil Diolamine26$71,445
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr127$66,166
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$38,089
Spiriva RespimatTiotropium Bromide34$30,830
Spiriva HandihalerTiotropium Bromide34$29,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckWinrevair$58$830,46459 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →